1. Home
  2. LKFN vs BEAM Comparison

LKFN vs BEAM Comparison

Compare LKFN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LKFN
  • BEAM
  • Stock Information
  • Founded
  • LKFN 1872
  • BEAM 2017
  • Country
  • LKFN United States
  • BEAM United States
  • Employees
  • LKFN N/A
  • BEAM N/A
  • Industry
  • LKFN Major Banks
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LKFN Finance
  • BEAM Health Care
  • Exchange
  • LKFN Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • LKFN 1.6B
  • BEAM 1.9B
  • IPO Year
  • LKFN 1997
  • BEAM 2020
  • Fundamental
  • Price
  • LKFN $61.60
  • BEAM $18.83
  • Analyst Decision
  • LKFN Buy
  • BEAM Strong Buy
  • Analyst Count
  • LKFN 2
  • BEAM 11
  • Target Price
  • LKFN $68.00
  • BEAM $48.90
  • AVG Volume (30 Days)
  • LKFN 215.3K
  • BEAM 2.5M
  • Earning Date
  • LKFN 07-25-2025
  • BEAM 08-12-2025
  • Dividend Yield
  • LKFN 3.25%
  • BEAM N/A
  • EPS Growth
  • LKFN N/A
  • BEAM N/A
  • EPS
  • LKFN 3.67
  • BEAM N/A
  • Revenue
  • LKFN $238,375,000.00
  • BEAM $63,578,000.00
  • Revenue This Year
  • LKFN $16.03
  • BEAM N/A
  • Revenue Next Year
  • LKFN $4.31
  • BEAM $17.18
  • P/E Ratio
  • LKFN $16.78
  • BEAM N/A
  • Revenue Growth
  • LKFN N/A
  • BEAM N/A
  • 52 Week Low
  • LKFN $50.00
  • BEAM $13.53
  • 52 Week High
  • LKFN $78.61
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • LKFN 40.54
  • BEAM 43.72
  • Support Level
  • LKFN $63.54
  • BEAM $19.89
  • Resistance Level
  • LKFN $68.79
  • BEAM $21.40
  • Average True Range (ATR)
  • LKFN 1.70
  • BEAM 1.27
  • MACD
  • LKFN -0.49
  • BEAM -0.33
  • Stochastic Oscillator
  • LKFN 2.97
  • BEAM 4.57

About LKFN Lakeland Financial Corporation

Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: